Loading
A phase 3 trial in pancreatic cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., not yet recruiting.
A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer is a phase 3, randomised interventional study registered as NCT06492941 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with a registry enrolment figure of 142 participants, started 2024-08-12 and due to reach its primary completion in 2026-04-14. Interventions recorded: Docetaxel for Injection (Albumin bound); Placebo; Best supportive care. Conditions listed: Advanced Pancreatic Cancer. Primary outcome: OS. Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed diagnosis of pancreatic cancer (including adenosquamous carcinoma)". No results are recorded here; the registry entry is the source.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.